Topical Corticosteroids Market Analysis & Forecast: 2026-2033
The Topical Corticosteroids market is estimated to be valued at USD 4.63 Bn in 2026 and expected to reach USD 6.15 Bn by 2033, witnessing a CAGR of 4.1% over the forecast period (2026-2033).
The topical corticosteroid industry is the biggest part of the worldwide dermatology drug industry. Topical corticosteroids are anti-inflammatory drugs that are directly placed on the skin to alleviate conditions like eczema, psoriasis, dermatitis, allergic reaction and inflammation of the skin. They work by lowering the swelling, redness, itching, or irritation of an affected area of the skin, and they do this through the suppression of immune system in the relevant area of skin.
There is a variety of formulations of topical corticosteroids that allow physicians to modify the treatment based on both severity of disease and patient skin type. These products are used frequently by physicians in hospitals, dermatology clinics and outpatient settings.
The growth of the topical corticosteroid industry is primarily driven by the growing number of chronic skin pathologies, the increase in knowledgeable consumers regarding the importance of the skin health, and the high availability of over-the-counter corticosteroids. In addition, developments in the delivery of dermatological drugs via methods of delivery and teledermatological consult have begun to expand patient access to topical corticosteroids.
|
Current Event |
Description and its Impact |
|
FDA Approval of New Dermatology Treatments |
|
|
Expansion of Teledermatology Services |
|
|
Pharmaceutical Partnerships in Dermatology R&D |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Image recognition technology is being increasingly used to identify and assess skin diseases through artificial intelligence (AI) in dermatology. In December 2025, the All India Institute of Medical Sciences (AIIMS) partnered with Google to develop Indus Derma, an AI-powered dermatology app designed to improve access to skincare. The app uses advanced image analysis to help patients and non-specialist providers identify and manage common skin conditions.
AI technologies help dermatologists make more accurate diagnoses at an earlier stage for many skin conditions, such as eczema and psoriasis, which contributes to the precise and timely delivery of topical corticosteroids.
The use of complimenting medical AI apps developed specifically for dermatology provides prescribers with assistance in making accurate determinations of various inflammatory skin disorders, which leads to increased access to corticosteroid prescriptions.
Creams represented 42.3% of revenue in the global topical corticosteroids market by 2026. Due to higher patient adherence compared with other formulations, as well as being non greasy and having an optimal rate of absorption, creams are the leading product category. Creams treat eczema, dermatitis, and allergic skin responses effectively because they offer anti-inflammation while providing minimal skin occlusion. Creams are also preferred option for use on areas with delicate or sensitive skin. For instance, dermatologists frequently write prescriptions for hydrocortisone creams used as a first-line agent for mild inflammation of the skin.
In 2026, the topical corticosteroid market for dermatitis is expected to hold 38.6% of the market. The dermatitis segment led the way because there is a higher incidence of irritant dermatitis and allergic contact dermatitis worldwide. Exposure to Allergens, Chemicals and pollution are all contributing factors to the rise in dermatitis cases, particularly in urban areas. As such, topical corticosteroids are commonly prescribed to treat and relieve symptoms of dermatitis by reducing inflammation, redness, and itching. Occupations in the healthcare field, due to the high rates of dermatitis have seen many Healthcare workers using creams with betamethasone-based corticosteroids to treat their irritant dermatitis from working with hazardous materials.
The global topical corticosteroids market is anticipated to have a share of approximately 46.8% provided to return pharmacies in 2026. The retail pharmacy sector has dominated the market for topical steroids primarily because of the wide availability of over-the-counter as well as prescription topical forms of steroid medications. Retail pharmacies are also the most accessible source of healthcare for patients needing immediate treatment for a minor skin condition. Many patients use pharmacist consultation services to help them determine which corticosteroid product is right for them, for example purchasing hydrocortisone cream from the pharmacy for an allergic skin reaction.
To learn more about this report, Download Free Sample
North America is anticipated to account the dominant share of 42.50% in 2026. The North American market for topical corticosteroids is significant worldwide, as North America has the best general medical practices to treat skin disorders, with many pharmaceutical companies focused on developing new medication to treat skin disease. North America also has strong dermatology networks and sufficient access through the national government for affordable and readily available topical corticosteroids to treat diseases like eczema, psoriasis and dermatitis.
The topical corticosteroids market is anticipated to grow at an exceptionally high rate in Asia and the Pacific regions, with this increase attributed to rapid urbanization, increased spending on healthcare, and greater knowledge of the prevalence of dermatologic disorders. The rise in disposable income the expansion of pharmaceutical manufacturing, and improved access to dermatology treatments are all contributing to the increased uptake of tropical cortical steroid products in several emerging markets throughout the Asia Pacific region.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.63 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.1% | 2033 Value Projection: | USD 6.15 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
GlaxoSmithKline plc, Merck & Co., Inc., Sandoz International GmbH, AstraZeneca, LEO Pharma, Cipla Inc., Bristol-Myers Squibb Company, Almirall, S.A., Bausch Health, and Sanofi SA |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Chronic inflammatory skin disorders such as Eczema, Psoriasis and dermatitis are rapidly increasing throughout the world. There are several causes that have contributed to the increased incidence of these chronic skin diseases, such as pollution in the environment, allergens in the air, lifestyle stress, and genetic makeup. The increased number of patients who require topical corticosteroids, which are first line therapies for many dermatological diseases, will greatly influence the growth of the market worldwide.
From healthcare campaigns to public awareness of skin health and dermatological treatments via social media, public awareness of skin health and dermatological treatments has been greatly increased. More and more consumers are looking for medical treatments for their skin irritation, allergies and cosmetic concerns and this has greatly increased the use of topical corticosteroids globally.
Through the past expansion of telemedicine, patients can use telemedicine platforms to consult a dermatologist through a remote consultation and get their dermatological prescription promptly. Additionally with online pharmacies, prescription topical medications are easily accessible for patients living in rural and underserved communities creating significant opportunities for both pharmaceutical manufacturers and digital healthcare service providers.
On July 23, 2025, the U. S. Food and Drug Administration approved delgocitinib (Anzupgo) cream, developed by LEO Pharma, for treatment of adults with moderate-to-severe chronic hand eczema, expanding advanced topical therapy options for inflammatory skin conditions.
Share
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
